RECENT COMMENTS

Rajesh Kumar: Is it helpfull for Overian cancer patient at advance stage? Rajesh Kumar +919681303310   »Read more

Cindy: I'm not a medical professional. My mother has been diagnosed with CUP - and was treated several year [...]   »Read more

Rajesh Kumar: +919681303310.   »Read more

Rajesh Kumar: Please write your comment here   »Read more

christian: Is gabapentin has been proposed to treat peripheric neuropathy induced by chemotherapy. At low dosa [...]   »Read more

 

Article type: Cover Story

Keywords: Ulrik Ringborg, comprehensive cancer centres, health services, OECI, .

This article has 0 comments

Facebook Twitter Share - Send - Print - Pdf

 

Ulrik Ringborg: tackling the fragmentation of Europe’s cancer efforts

Ulrik Ringborg:
tackling the fragmentation of
Europe’s cancer efforts

Ulrik Ringborg remembers a time before pressure on cancer services led Sweden to abandon a model that combined clinical and research responsibilities. He believes comprehensive cancer centres, similar to those in the US, are key to restoring that link, and could provide the backbone to unify efforts to improve cancer care in Europe.

» Marc Beishon


To read the complete article please click on the pdf icon

 
COMMENTS (0)
When submitted, your comment will be moderated. Messages which may be considered defamatory, which incite hatred or contain foul or abusive language, or are gratuitously offensive, will not be published. Please ensure that your comments are concise and relevant to the topic in question. Off-topic comments and comments without a username will not be published.

ESO reserves the absolute right not to publish comments.
  Name (required)
  E-mail (will not be published) (required)
  Captcha code (required)

CancerWorld invites you to visit:

 
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, Celgene, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Merck Serono, Novartis, Roche and Sanofi Aventis.